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Abstract
WHO guidelines recommend immediate initiation of antiretroviral therapy (ART) for all 
individuals at HIV diagnosis regardless of CD4 count, but concerns remain about potential low 
uptake or poor adherence among healthy patients with high CD4 counts, especially in resource-
limited settings. This study assessed the acceptability of earlier treatment among HIV-positive 
South African women, median age at enrollment 25 (IQR 22–30), in a 10-year prospective cohort 
study by (i) describing temporal CD4 count trends at initiation in relation to WHO guidance, (ii) 
virological suppression rates post-ART initiation at different CD4 count thresholds, and (iii) 
administration of a standardized questionnaire. 158/232 (68.1%) participants initiated ART 
between 2006 and 2015. Mean CD4 count at initiation was 217 cells/μl (range 135–372) before 
2010, and increased to 531 cells/μl (range 272–1095) by 2015 (p<0.001). Median viral load at 
ART initiation decreased over this period from 5.2 (IQR 4.6–5.6) to 4.1 (IQR 3.4–4.6) log 
copies/ml (p=0.004). Virological suppression rates at 3, 6, 12 and 18 months were consistently 
above 85% with no statistically significant differences for participants starting ART at different 
CD4 count thresholds. A questionnaire assessing uptake of early ART amongst ART-naïve 
women, median age 28 (IQR 24–33), revealed that 40/51 (78.4%) were willing to start ART at 
CD4 ≥500. Of those unwilling, 6/11 (54.5%) started ART within six months of questionnaire 
administration. Temporal increases in CD4 counts, comparable virological suppression rates, and 
positive patient perceptions confirm high acceptability of earlier ART initiation for the majority of 
patients.
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In 2013, the World Health Organization (WHO) issued revised HIV treatment guidelines, 
recommending to initiate antiretroviral therapy (ART) at a CD4 count threshold of 500 cells/
μl for HIV-positive individuals [1]. Modeling exercises have estimated that implementation 
of these guidelines would save 3 million lives and prevent over 3.5 million new HIV 
infections between 2013 and 2025 [2]. In 2015, these guidelines were updated 
recommending ART initiation at any CD4 count, also known as the ‘Test and Treat’ strategy, 
where ART is immediately initiated at the time of HIV diagnosis [3].
Benefits of early ART initiation include better immune recovery, reduced risk of HIV 
transmission, and a lower chance of developing HIV-related diseases such as cardiovascular, 
kidney and liver diseases, neurological complications and cancers [48]. Recent randomized 
multicenter studies have demonstrated reductions in both morbidity and mortality among 
HIV-positive individuals when starting ART at a CD4 count threshold of 500 cells/μl as 
compared to deferring therapy [9, 10]. Furthermore, the latest ART treatment regimens are 
more convenient, better tolerated, and more effective than older regimens, thus reducing the 
burden on the patient of starting treatment at an earlier stage during the disease [11, 12]. 
Despite the recent evidence and WHO guidance, questions remain at the individual patient 
level about balancing the benefits and potential drawbacks of earlier ART, such as side 
effects, long-term adherence, development of drug resistance, and increased cost of life-long 
therapy.
As the evidence for early ART increases, it is important to understand how patients perceive 
starting treatment earlier. Guidelines have less impact if patients or clinicians do not find 
them acceptable. It is therefore important to understand how CD4 count and viral load at 
ART initiation have changed over time in relation to changing WHO guidelines. In addition, 
few studies have examined patient acceptability of early ART, especially in resource-limited 
settings. Of the studies that have been conducted, most HIV-positive participants thought 
that initiating ART earlier would help maintain health and prevent HIV transmission, 
however, they were also concerned about side effects, adherence to life-long treatment, 
community acceptance, and stigma [13, 14]. Patient reasons for either acceptance or 
reluctance to initiate ART at higher CD4 counts are integral to informing both programmatic 
and policy decisions within South Africa and the wider global community.
The objective of this study was to assess the acceptability of earlier ART in a 10-year 
prospective cohort study of HIV-positive South African women by (i) describing temporal 
trends of CD4 counts at ART initiation in relation to changing WHO guidance, (ii) 
determining virological suppression rates post-ART initiation at different CD4 count 
thresholds, and (iii) obtaining participant feedback through administration of a standardized 
questionnaire.
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A total of 232 women were enrolled at a median age of 25 (IQR 22 – 30) into the CAPRISA 
002 Acute Infection study, an ongoing prospective cohort study, which started in August 
2004. Participants were recruited at two sites within the province of KwaZulu-Natal in South 
Africa, an urban site in the city of Durban and a rural site in Vulindlela. The original aim of 
the study was to describe clinical, virologic and immunologic characteristics of HIV-1 
subtype C infection [15]. Women who seroconverted during the HIV-negative phase of 
CAPRISA 002 or during other CAPRISA seroincidence and prevention trials, including the 
CAPRISA 004 and CAPRISA 008 microbicide trials [16], were enrolled into the Acute HIV 
Infection phase, and then followed up during chronic infection, ART initiation, and up to 5 
years on ART. Additional information about CAPRISA 002, including the recruitment 
protocol and patient eligibility criteria, were reported previously [15, 17].
Study procedures
Once HIV infection was diagnosed, study participants had at least 3-monthly follow up 
visits, where clinical assessments including CD4 count (FACSCalibur Flow Cytometer or 
TruCOUNT, BD biosciences, San Jose, CA, USA) and HIV viral load measurements (Roche 
Cobas Amplicor v.1.5, Taqman version 1.0 or version 2.0, Roche Diagnostics, Switzerland) 
were performed. Participants were offered to start ART according to WHO guidance, usually 
slightly ahead of its adoption by the South African treatment guidelines (Figure 1). The first 
participants started ART at a CD4 count threshold of <200 cells/μl in 2006. In 2010, WHO 
guidance changed to a treatment threshold of ≤350 cells/μl, while in South Africa only 
pregnant women, tuberculosis co-infected patients or those with AIDS-defining illness were 
eligible for ART at this threshold. This guidance was extended to the rest of the South 
African HIV positive population in 2013. In June 2013, the WHO recommended treatment 
at ≤500 cells/μl, which was then expanded to universal treatment in 2015. South Africa 
moved to a threshold ≤500 cells/μl in 2015, and recently introduced universal treatment in 
September 2016. Since January 2015, slightly ahead of the guidelines, participants of the 
CAPRISA 002 study have been offered to start ART at a CD4 count of 500 cells/μl or above, 
essentially offering immediate therapy, irrespective of CD4 count. Once on ART, 
participants were followed up at 1, 3, 6, 12 months after initiation, and 6-monthly thereafter. 
For the purpose of this study, virological suppression was defined as viral load <400 
copies/ml, because this was the detectability threshold for the original Roche COBAS 
Amplicor version 1.5 assay allowing comparison over time. Ethical approval for the 
CAPRISA 002 study and the Acceptability Questionnaire were granted by the local 
Biomedical Research Ethics Committee (BREC) (#E013/04).
Early ART questionnaires
Between November 2014 and May 2015 a cross-sectional questionnaire was administered at 
both study sites to assess participant acceptability and perceptions of early ART initiation. 
CAPRISA 002 participants were eligible for the questionnaire, if they were ART-naïve and 
were willing to provide consent (n=51). Questionnaires were administered by a study nurse 
in either English or the local language, isiZulu, and assessed the level of agreement of 
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participants with statements sourced from the literature. The questionnaire was created to 
gauge the willingness of participants to initiate ART at CD4 count 500 cells/μl or above, 
perceived benefits and drawbacks of early ART initiation for the individual and the public, 
and partner information, including the partner’s HIV and ART status and disclosure. Some 
questions required a yes or no answer, while others provided a number of predetermined 
answers and participants were instructed to choose as many as apply. There was also an 
option for each question that allowed participants to specify an additional answer that was 
not listed. For example, patients were asked if they were willing to start treatment at ≥500 
cells/μl and instructed to check the box marked either ‘yes’ or ‘no’. A subsequent question 
stated that if a participant indicated that they were willing to start treatment at ≥500 cells/μl 
then they should provide all reasons for their willingness to do so. The answers that were 
listed were 1) ‘I feel ready to start treatment’, 2) ‘I want to improve my health’, 3) ‘I am 
planning to have a baby’, and 4) ‘I want to reduce my chances of getting tuberculosis’, and 
5) ‘Other: Specify’. Patients were given different answers to select if they responded that 
they were currently unwilling to initiate ART at ≥500 cells/μl. In addition, patients were 
asked if they considered any of the listed factors important benefits of HIV treatment. These 
potential benefits were divided into two categories: potential individual benefits and 
potential public health benefits and participants were instructed to select all that apply as 
well as given an option to specify an answer that was not included in the questionnaire. 
Questionnaires were recorded as case report forms and faxed into the CAPRISA Data 
Management Centre, using the DataFax system version 2014.1.1 (Clinical DataFax Systems 
Inc., Ontario, Canada). Data from subsequent CAPRISA 002 visits were then used to verify, 
whom of the 51 participants completing the questionnaire went on to initiate ART, and at 
what CD4 count.
Statistical methods
Characteristics of the study participants were summarized using descriptive statistics 
expressed as means with standard deviation (SD) or medians with interquartile ranges (IQR) 
for continuous variables and proportions for categorical variables. An independent samples 
t-test was used to compare two means of continuous variables, while the Wilcoxon-Mann-
Whitney test was used to compare two medians. Proportions were compared using Fisher’s 
exact test. The significance of the trend of a continuous variable was assessed with a t-test. 
All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and graphs were prepared using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, 
USA).
Results
CD4 count and viral load trends at ART Initiation in CAPRISA 002
A total of 232 HIV-positive women were enrolled into the CAPRISA 002 acute infection 
study. Of these, 158 (68.1%) initiated ART between January 2006 and December 2015, and 
were included in the analysis. Of the remainder, 32 (13.8%) had not started therapy, 23 
(9.9%) started therapy in another treatment study or at their local clinic, 11 (4.7%) were lost 
to follow-up, 4 (1.7%) died, and 4 (1.7%) had incomplete data available. The mean CD4 
count at initiation was 217 cells/μl (range 135 – 372) before 2010, and gradually increased 
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to 531 cells/μl (range 272 – 1095) in 2015 (p<0.001). The median viral load simultaneously 
decreased from 5.2 (IQR 4.6 – 5.6) to 4.1 (IQR 3.4 – 4.6) log copies/ml (p=0.004) (Figure 
1).
Virological suppression rates stratified by CD4 count treatment thresholds
The proportion of participants who achieved virological suppression, defined as a viral load 
result of <400 copies/ml, at 3, 6, 12 or 18 months after ART initiation was analyzed. 
Participants were stratified according to whether they started ART below or above two CD4 
count thresholds of 350 and 500 cells/μl. Overall, suppression rates were high at greater than 
86% for all participants at all time-points. There was no statistically significant difference 
between virological suppression at 3, 6, 12 or 18 months when comparing those who started 
below and above 350 or 500 cells/μl (Table 1).
Early ART questionnaire
A total of 51 ART-naïve CAPRISA 002 participants were eligible and completed the early 
treatment questionnaire. All participants were female with a median age of 28 (IQR 24–33), 
and 28/51 (54.9%) were from the rural research site. The majority were unmarried, but with 
a regular partner (44/51, 86.3%) and almost one half (24/51, 47.1%) were employed. Three 
quarters (37/51, 72.5%) indicated that they had disclosed their HIV status to their partner. At 
the time of questionnaire administration, participants had a mean CD4 count of 590 cells/μl 
(range 260 – 1450) and a median viral load of 4.1 log copies/ml (IQR 3.7 – 4.5).
Perceived individual and public health benefit of ART
Participants were asked if they agreed with various statements about the individual and 
public health benefits of treatment with ART. More than 80% of participants agreed that the 
listed outcomes were important benefits of HIV treatment including reduced risk of 
contracting tuberculosis (48/51, 94.1%), reduced disease and death (47/51, 92.2%), and 
reduced organ disease (43/51,84.3%). Furthermore, the majority considered reduced 
transmission during pregnancy (46/51, 90.2%), during breastfeeding (43/51, 84.3%), and to 
a partner (45/51, 88.2%) important public health benefits (Figure 2A). Participant beliefs 
about important risks and drawbacks of treatment varied in a ‘yes’ versus ‘no’ question. 
Some participants were concerned about side effects to treatment (30/51, 58.8%), the need 
for lifelong therapy (19/51, 37.3%), having to take treatment everyday (18/51, 35.3%), 
having to disclose the HIV status because of treatment (29/51,56.9%), and fear of stigma 
(29/51, 56.9%) (Figure 2B).
Willingness to start early treatment
Of the 51 women who completed the questionnaire, 40 (78.4%) were willing, while 11 
(21.6%) were unwilling to start ART at a CD4 count ≥500 cells/μl. Of those willing, 28 
(70%) stated that they felt ready to start treatment, 36 (90%) wanted to improve their health, 
25 (62.5%) wanted to reduce their chances of contracting Tuberculosis, and 12 (30%) were 
planning a pregnancy (Figure 3A). Of the 11 women who were unwilling to start ART at 
CD4 ≥500 cells/μl, 10 (90.9%) stated that they felt well and therefore did not think they 
needed ART. Less important reasons why women did not want to initiate ART at CD4 ≥500 
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cells/μl were their concerns about medication side effects (5/11,45.5%), high pill burden 
(3/11,27.3%), and having to disclose their HIV status to the partner or to family members 
(3/11,27.3%) (Figure 3B).
High HIV prevalence and low ART coverage among male partners
Of the 51 participants who responded to the questionnaire, 48 women (94.1%) stated that 
they had a current regular partner, one woman (2.0%) had a casual partner and two women 
(3.9%) had no current partner. A total of 27/49 (55.1%) knew their partner’s status, with 
22/27 (81.5%) of these partners being identified as HIVpositive. However, only 5/22 
(22.7%) of them were reported to be on ART by the women.
Perception and reality of ART Initiation
Of the 51 women participating in the questionnaire, 35 (68.6%) initiated therapy within 6 
months of questionnaire administration. Of the 40 participants who indicated that they were 
willing to initiate at CD4 ≥500, 29 (72.5%) started treatment at a mean CD4 count of 717 
cells/μl (range 377 – 1191). Of the 11 participants unwilling to initiate at CD4 ≥500, 6 
(54.5%) initiated ART within 6 months of questionnaire administration at a mean CD4 count 
of 690 cells/μl (range 322 – 1224). A total of 16/51 (31.4%) participants remained ART-
naïve with a mean CD4 count of 815 cells/μl (range 436 – 1254) at the end of 2015.
Discussion
The goal of this study was to investigate participant acceptability of early ART initiation by 
analyzing cohort CD4 count and viral load data, and through administration of a participant 
questionnaire. We found that CD4 counts at ART initiation have been dramatically 
increasing over the last decade, and that concurrently, HIV viral loads have decreased, 
potentially having an important impact on HIV transmission at the individual and 
community level. These results suggest the successful implementation of WHO and South 
African Department of Health guidelines, and reveal a history of acceptance of earlier ART 
initiation by HIV-positive South African women who were followed up for an extended 
period in the CAPRISA 002 cohort. Importantly, while women started ART earlier, this did 
not have a negative impact on their adherence, as demonstrated by similar rates of 
virological suppression up to two years post-ART initiation regardless of the CD4 count at 
treatment start.
Behavioral questionnaires in a subset of the women revealed that a majority of nearly 80% 
were willing to initiate ART at a CD4 count of 500 cells/μl or higher. This is an important 
finding that demonstrates that most patients will likely adhere to the WHO recommendations 
and initiate ART soon after HIV diagnosis as the policy becomes fully implemented and 
accepted in South Africa. This study also found that patient perceptions on when to start can 
differ from their actions. Approximately one quarter of women who indicated that they were 
willing to start treatment early did not start within six months. This could have been 
explained by logistical reasons, such as the visit schedule or due to adjustment to the 
diagnosis and general readiness. Conversely, more than half of the women who indicated 
that they were unwilling to start treatment at a CD4 count of 500 cells/μl, initiated at a CD4 
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count >500 cells/μl within six months, demonstrating that a discussion with health care 
professionals about the benefits of earlier ART can promote earlier initiation among 
concerned patients. One study on ART initiation in the United States found that education 
and provider recommendation of ART were the most important factors in a patient’s 
decision to initiate treatment [18].
Other important factors relating to ART initiation include partner notification and disclosure. 
If patients do not disclose their status to partners or other family members, it can dissuade 
them from initiating ART, especially if they currently feel healthy. Only one half of 
questionnaire participants knew their partners’ status, and the majority of these partners 
were identified as HIV-positive, consistent with high rates of heterosexual transmission in 
this population. The low ART coverage among partners highlights the need for increased 
HIV testing strategies targeting males, but also couple counselling with regards to partner 
diagnosis and early ART initiation as a couple.
The main reason study participants stated for not wanting to initiate ART at a higher CD4 
count was that they felt well and therefore did not see the need for therapy. There appears to 
be a common belief that ART does not need to be initiated until one begins to feel sick and 
demonstrate signs of more advanced HIV progression [19]. This shows that the results from 
recent studies [9, 10], which clearly demonstrate the benefits of earlier ART initiation still 
need to be communicated effectively to patients, so that informed decisions on treatment 
start can be made.
This study had some limitations. Firstly, the study population consisted of young South 
African women, meaning that results on early ART initiation cannot necessarily be 
generalized to men, children, and older populations. Secondly, these women have been 
participating in a prospective cohort study with regular clinic visits for some time, 
suggesting that this population might be more knowledgeable about ART, more health 
conscious, or more likely to act on health professionals’ advice than the general population. 
Finally, the questionnaire was administered to a relatively small number of women, and may 
not have covered all possible reasons for ART refusal, which may be relevant to other 
regions in South Africa or globally.
In this study we have shown that earlier ART initiation is acceptable to the majority of 
participants as evidenced by the increasing CD4 count at ART initiation over time and high 
levels of virological suppression among women regardless of CD4 count at treatment start. 
Although some concerns remain about side effects, stigma, and disclosure, appropriate 
education and counseling by healthcare professionals can encourage patients to start early 
and successful HIV therapy. At a programmatic level this may mean that ART initiation 
visits should be prioritized to ensure sufficient time is allocated to explain to newly 
diagnosed patients, the individual and prevention benefits of early ART. Our study suggests 
that men may not be accessing ART programs as readily as women. Future studies should 
investigate the acceptability of early ART among men in order to inform programming.
The decision by the South African Department of Health to implement universal treatment 
made more than two million additional people eligible for ART [20]. Considering this 
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commitment, it is now important to allocate sufficient resources for HIV testing and 
treatment, and to monitor the quality of these programs, so that all patients and communities 
can reap the individual and population level benefits of early ART initiation.
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Figure 2. A and B: Perceived benefits and drawbacks of earlier ART (n=51)
Tx = transmission
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A and B: Acceptability of ART initiation at CD4 ≥500 (n=51)
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Table 1
Virological Suppression stratified by CD4 count at ART Initiation

































P-value 1.000 1.000 0.357 1.000
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